Harvard Spinout Magenta, Other Academics Race Toward Better Stem Cell Transplants – Xconomy
Xconomy |
Harvard Spinout Magenta, Other Academics Race Toward Better Stem Cell Transplants
Xconomy Stem cell transplants are risky business, and although their use to treat cancer and other blood-borne diseases has increased in recent years, they remain dangerous and in many cases a last resort. One startup using work from Harvard University wants … Stem Cell Transplant Startup With Harvard Tech, Magenta Therapeutics, Gets $48.5M Atlas, Third Rock join forces to launch new stem cell upstart Doug Oliver Was Legally Blind. After an Adult Stem Cell Treatment He Can See Again |
